Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis
Open Access
- 1 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics - Open
- Vol. 4 (4), 625-633
- https://doi.org/10.1007/s41669-020-00211-0
Abstract
Background No willingness-to-pay (WTP) per quality-adjusted life-year (QALY) value exists for the Kingdom of Saudi Arabia (KSA). Objective The primary objective of this study was to determine the WTP for a QALY in the KSA. Methods Adult citizens of the KSA, patients with cancer, or members of the general public (MGP) were recruited to participate in a time trade-off survey to elicit health utilities. Cancer was chosen as the disease of interest for patients and the MGP, with a scenario describing stage 3 colorectal cancer, because it is a disease condition that impacts on both quality of life and survival time. In a second step, respondents were asked about their WTP to move from the estimated health state to a state of perfect health for 1 year (QALY). Finally, that amount was processed to generate the WTP for a full QALY. The second step was repeated with a 5-year horizon. Sensitivity analyses were performed without outliers. Results From 400 participants, data from 378 subjects were obtained and usable: 177 patients, 201 MGP; 278 male, 100 female subjects; 231 aged 26-65 years. Demographic distribution varied widely between the two subgroups for age, education level, and employment status, but with less variation in sex and income. Elicited health utilities were 0.413 (0.472 after adjustment) for the overall group, 0.316 (0.416) for patients, and 0.499 (0.508) for MGP. Overall WTP for a QALY was $US25,600 (adjusted $US32,000) for the 1-year horizon and $US19,200 (adjusted $US22,720) for the 5-year horizon. Conclusion This was the first empirical attempt to estimate the WTP per QALY for the KSA. Results are comparable to those in some other countries and to gross domestic product figures for the KSA. Further research in a country-wide sample is warranted.Funding Information
- Pfizer
- Bristol-Myers Squibb
- Sanofi
- Bayer
This publication has 20 references indexed in Scilit:
- On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic reviewGlobal Health Action, 2018
- Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness thresholdHealth Technology Assessment, 2015
- RELATIONSHIP BETWEEN FINANCIAL IMPACT AND COVERAGE OF DRUGS IN AUSTRALIAInternational Journal of Technology Assessment in Health Care, 2012
- An economic evaluation of an abdominal aortic aneurysm screening program in ItalyJournal of Vascular Surgery, 2011
- Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICEHealth Economics, Policy and Law, 2011
- Cost-effectiveness of treatment with etanercept for psoriasis in SwedenThe European Journal of Health Economics, 2011
- Methylnaltrexone in the Treatment of Opioid-Induced Constipation in Cancer Patients Receiving Palliative Care: Willingness-to-Pay and Cost-Benefit AnalysisJournal of Pain and Symptom Management, 2011
- Willingness to Pay for a Quality-Adjusted Life-Year: The Individual PerspectiveValue in Health, 2010
- Willingness to Pay for a Treatment for Pain in Multiple SclerosisPharmacoEconomics, 2009
- Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Review of Pharmacoeconomics & Outcomes Research, 2008